Abstract:Background & Aims Accumulating evidence has indicated the presence of mature miRNAs in the nucleus, but their effects on steatohepatitis remain elusive. We have previously demonstrated that the intranuclear miR-204-3p in macrophages protects against atherosclerosis, which shares multiple risk factors with metabolic dysfunction-associated steatotic liver disease (MASLD). Herein, we aimed to explore the functional significance of miR-204-3p in steatohepatitis. Methods miR-204-3p levels and subcellular localization were assessed in the livers and peripheral blood mononuclear cells (PBMCs) of MASLD patients. Wild-type mice fed a high-fat diet (HFD) or methionine- and choline-deficient (MCD) diet were administered an adeno-associated virus system containing miR-204-3p to determine the effect of miR-204-3p on steatohepatitis. Co-culture systems were applied to investigate the crosstalk between macrophages and hepatocytes or hepatic stellate cells (HSCs). Multiple high-throughput epigenomic sequencings were performed to explore miR-204-3p targets. Results miR-204-3p expression decreased in the livers and macrophages in mice and patients with fatty liver. In MASLD patients, miR-204-3p levels in PBMCs were inversely related to the severity of hepatic inflammation and damage. Macrophage-specific miR-204-3p overexpression reduced steatohepatitis in HFD- or MCD diet-fed mice. miR-204-3p-overexpressing macrophages inhibited TLR4/JNK signaling and pro-inflammatory cytokine release, thereby limiting fat deposition and inflammation in hepatocytes and fibrogenic activation in HSCs. Epigenomic profiling identified miR-204-3p as a specific regulator of ULK1 expression. ULK1 transcription and VPS34 complex activation by intranuclear miR-204-3p improved autophagic flux, promoting the anti-inflammatory effects of miR-204-3p in macrophages. Conclusions miR-204-3p inhibits macrophage inflammation, coordinating macrophage actions on hepatocytes and HSCs to ameliorate steatohepatitis. Macrophage miR-204-3p may be a therapeutic target for MASLD. Impact and implications Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic inflammatory disease ranging from simple steatosis to non-alcoholic steatohepatitis. However, the molecular mechanisms underlying the progression of MASLD remain incompletely understood. Here, we demonstrate that miR-204-3p levels in circulating peripheral blood mononuclear cells are negatively correlates with disease severity in patients with MASLD. Nuclear miR-204-3p activates ULK1 transcription and improves autophagic flux, limiting macrophage activation and hepatic steatosis. Our study provides a novel understanding of the mechanism of macrophage autophagy and inflammation in steatohepatitis and suggests that miR-204-3p may act as a potential therapeutic target for MASLD.

Reduced ZMPSTE24 expression leads to prelamin accumulation and development of steatosis in MASLD patients.

Zinc finger BED-type containing 3 promotes hepatic steatosis by interacting with polypyrimidine tract-binding protein 1

HNF4α-CDKL3 Axis Restricts MASLD Progression by Targeting FoxO1 Via Non-Canonical Phosphorylation

TM6SF2 E167K Variant Decreases PNPLA3-mediated PUFA Transfer to Promote Hepatic Steatosis and Injury in MASLD

Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression

Updated mechanisms of MASLD pathogenesis

Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD)

Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment

IDDF2024-ABS-0412 Intestinal NLRP3 Deficiency Aggravates MASLD Mice Via Reduced Butyrate Production

Liver B Cells Promotes MASLD Progression via the Apelin/APLNR System

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD

Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice

Metabolic Dysfunction-Associated Steatotic Liver Disease Is Accompanied by Increased Activities of Superoxide Dismutase, Catalase, and Carbonyl Reductase 1 and Levels of miR-200b-3p in Mouse Models

LNCHC directly binds and regulates YBX1 stability to ameliorate metabolic dysfunction‐associated steatotic liver disease progression

USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination

Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice

Knockdown of the Clock gene in the liver aggravates MASLD in mice via inhibiting lipophagy

LncRNA Aggravates Hepatic Steatosis via PPARγ Signaling

Mettl3-m6A-YTHDF1 axis promotion of mitochondrial dysfunction in metabolic dysfunction-associated steatotic liver disease

Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy

Elevated Porcupine Disrupts Lipid Metabolism and Promotes Inflammatory Response in MASLD